



Oct 1st, 2021
Whiz Partners Inc.

Establishment of Healthcare New Platform Fund Limited Partnership

Whiz Partners Inc. (Tokyo, Japan; President and CEO Atsushi Matsumura) (“Whiz Partners”) has established the Healthcare New Platform Fund Investment Partnership (“HNP Fund” or the “Fund”) on 28th September, 2021.

Summary of NFP Fund in below;

Name of the Fund	Healthcare New Platform Fund Limited Partnership
Place of Registry	2-5-1 Atago, Minato-ku Tokyo
General Partner (GP)	Whiz Partners Inc.
Target Fund Size	JPY 50 Billion
Final Closure	End of August , 2022
Management Period	September 28 th , 2021 ~ December 31 st , 2031 (Fiscal period end :December) ※ 3 year extensions may be granted annually with the consent of 2/3 (two thirds) of all LPs

HNP Fund is planning to invest mainly in new healthcare platform companies, such as “Axcelead, Inc.”, the first healthcare platform company in Japan, and CDMO company “ARCALIS, Inc.” which will build a Japan’s first and only plant of APIs and formulations for mRNA drugs and vaccines in Minami-soma, Fukushima.

These investees will continue to grow their businesses with the aim of IPOs in Japan and overseas. For an overview of HNP Fund's portfolio companies, please refer to their websites (https://www.axcelead-hd.com/?page_id=378) and business introduction movies (https://www.axcelead-hd.com/?page_id=430).



About Whiz Partners, Inc.

Whiz Partners, Inc. (Tokyo, Japan) is an alternative asset management firm with Growth Equity and Global Macro Hedge fund offerings. Whiz Partners has a strong track record, not only in Healthcare investments but also in information technology and AI. For more information about Whiz Partners, please visit their website <http://www.whizp.com>.

Contact; Eri Yokota

yokota@whizp.com

* The equity interest of the Fund is not a suitable product for all investors. Only investors who are qualified institutional investors or meet certain requirements (Article 17-12, Paragraph 1, Items of the Enforcement Order of the Financial Instruments and Exchange Law, and Article 233-3, Paragraph 1, Items of the Cabinet Office Ordinance on Financial Instruments Business, etc. as a person other than a qualified institutional investor who has knowledge and experience in investment) such as listed companies and companies with capital of 50 million yen or more, may acquire it.

* When considering investment in the Fund, please carefully read the Agreement of the Fund and the Pre-Contract Document regarding the terms and conditions of the Fund. Please make your own judgment after seeking the opinions of legal, tax, accounting and other experts as necessary.

* Please click [here](#) for the Fund's overview, fees and expenses, risks, and other points to note.